Abstract 4305
Background
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare Epstein-Barr virus (EBV) associated cancer, histologically indistinguishable from nasopharyngeal carcinoma (NPC). Somatostatin receptor type 2 (SSTR2) is a bonafide theranostic target in neuroendocrine tumour. It is also demonstrably expressed in NPC, with autoradiography and positron emission tomography (PET). SSTR2 expression has not been reported in PLELC. In this study, we aimed to investigate SSTR2 expression and its co-localization with EBV positive PLELC cells using immunohistochemistry (IHC); and to investigate the clinical significance of SSTR2 in PLELC.
Methods
Clinical demographics including age, gender, TNM staging, EBV titre, smoking status, survival and treatment regime were collected. Archival formalin fixed, paraffin embedded (FFPE) tissue from patients diagnosed with PLELC between 2003 and 2016 at National Cancer Centre Singapore were retrieved and studied retrospectively. IHC staining for SSTR2 and Epstein-Barr encoding region in-situ hybridisation (EBER-ISH) were performed using a dual-staining technique.
Results
We report clinical data and dual staining from 20 PLELC patients. The median age at diagnosis was 56.5; 80% (16/20) of the patients were female; all non-smokers (except 3 with unknown status); 55% (11/20) of the patients had stage IV disease and the rest stage I-IIIB. High serum EBV titres were also noted in PLELC patients. Sixteen out of 20 patients (80%) stained positive for SSTR2 on IHC. SSTR2 expression co-localised with EBER positive cells. Nine out of 11 (82%) patients with stage IV PLELC stained positive for SSTR2 while 7 out of 9 (78%) stage I-III disease stained positive. Two year OS by SSTR2 status is 100% in SSTR2 negative and 65.2% (CI 35.1, 84.0) in SSTR2 positive patients, p = 0.467 by Log Rank Test. Two year OS by stage is 85.7% (CI 33.4, 85.7) for stage I-III and 63.6% (CI 29.7, 84.5) for stage IV disease, p = 0.014.
Conclusions
In PLELC, high levels of SSTR2 IHC expression is reported with co-localisation with EBV infected cells. A high proportion of stage IV patients have SSTR2 positive tumours. These patients have limited treatment options. This study opens up the possibility of using SSTR2 theranostics for these patients.
Clinical trial identification
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
National Cancer Centre Singapore Research Fund.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract